Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Male

Summary

A study to assess safety and tolerability of AZD2171 after multiple doses in patients with advanced prostate cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Cediranib

Criteria

Inclusion Criteria:

• Men, 18yrs and older

• Histological or cytological confirmation of prostate adenocarcinoma (symptomatic or asymptomatic)

• Prior hormonal therapy, and/or no more than 1 prior chemotherapy regimen (including estramustine and/or corticosteroids) for treatment of prostate adenocarcinoma

Exclusion Criteria:

• Prior radiotherapy to bone metastases within 4 weeks prior to screening

• any unresolved chronic toxicity greater than CTCAE grade 2 from previous anticancer therapy

• Brain metastases or spinal cord compression, unless treated at least 4 weeks before entry, and stable with steroid treatment for 1 week.